<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02801903</url>
  </required_header>
  <id_info>
    <org_study_id>NI-AC103</org_study_id>
    <nct_id>NCT02801903</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris</brief_title>
  <official_title>A Phase 1, Single-center, Open-label Pharmacokinetic, Safety and Tolerability Study of SB204 in Adolescents With Moderate to Severe Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>WCCT Global</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novan, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 21 day, single-center, open-label pharmacokinetic, safety and tolerability study in
      adolescents with moderate to severe acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 7, 2016</start_date>
  <completion_date type="Actual">August 25, 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of hMAP3 as measured by the maximum observed plasma concentration</measure>
    <time_frame>Day 21</time_frame>
    <description>Maximum plasma concentration of plasma hMAP3 on Day 21</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC - area under the plasma concentration time curve for hMAP3</measure>
    <time_frame>Day 21</time_frame>
    <description>AUC; area under the plasma concentration time curve from t=0 to the last measurable concentration for plasma hMAP3 on Day 21</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics as measured by maximum concentration of nitrate</measure>
    <time_frame>Day 21</time_frame>
    <description>Cmax: maximum plasma concentration of plasma nitrate on Day 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (AUC) - area under the plasma concentration time curve for hMAP3</measure>
    <time_frame>Day 21</time_frame>
    <description>AUC; area under the plasma concentration time curve from t=0 to the last measurable concentration for plasma nitrate on Day 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile (Reported adverse events)</measure>
    <time_frame>Day 21/End of Treatment</time_frame>
    <description>Reported adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability (Scores on tolerability assessment)</measure>
    <time_frame>Day 21/End of treatment</time_frame>
    <description>Scores on tolerability assessment during treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>SB204 4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topically Once Daily (AM)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB204 4%</intervention_name>
    <description>Topically Once Daily (AM)</description>
    <arm_group_label>SB204 4%</arm_group_label>
    <other_name>NVN1000</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Otherwise healthy male and female adolescent subjects with moderate to severe acne
             vulgaris on a 5 point IGA scale

          -  At least 20 total inflammatory lesions (papules and pustules), and at least 20 total
             non-inflammatory lesions (open and closed comedones) on the face, chest, back, and
             shoulders

          -  Age 9-16 years, 11 months inclusive

          -  Subjects with methemoglobin level less than 3% at Screening and Baseline by pulse
             co-oximeter

        Exclusion Criteria:

          -  Subjects with any other acne-like dermatological conditions such as severe,
             recalcitrant nodulocystic acne, acne conglobata, acne fulminans, acne secondary to
             medications or other medical conditions, perioral dermatitis, clinically significant
             rosacea, or gram-negative folliculitis;

          -  Any subject with skin disorders of an acute or chronic nature including psoriasis,
             eczema, tinea versicolor, etc.

          -  Subjects who reside in a dwelling that relies on well water for a primary drinking
             source

          -  Subjects with facial hair (beards, mustaches, etc.), tattoos or other facial markings
             that would interfere with assessments and study drug application

          -  Transgender subjects receiving hormone supplement (male to female or female to male)

          -  Subjects with a previous history of methemoglobinemia or taking medications known to
             be associated with methemoglobinemia

          -  Subjects with a known history of HIV, hepatitis, or other blood-borne pathogens

          -  Females who are pregnant, planning a pregnancy or breastfeeding

          -  Subjects previously treated with NVN1000 Gel / SB204
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M. Joyce Rico, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novan, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WCCT #1</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

